Jasmohan S Bajaj1, K Rajender Reddy2, Jacqueline G O'Leary3, Hugo E Vargas4, Jennifer C Lai5, Patrick S Kamath6, Puneeta Tandon7, Florence Wong8, Ram M Subramanian9, Paul Thuluvath10, Andrew Fagan11, Melanie B White11, Edith A Gavis11, Tejasav Sehrawat6, Randolph de la Rosa Rodriguez7, Leroy R Thacker12, Masoumeh Sikaroodi13, Guadalupe Garcia-Tsao7, Patrick M Gillevet13. 1. Department of Medicine, Virginia Commonwealth University and McGuire VA Medical Center, Richmond, Virginia. Electronic address: Jasmohan.bajaj@vcuhealth.org. 2. Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 3. Department of Medicine, Baylor University Medical Center, Dallas, Texas. 4. Department of Medicine, Mayo Clinic, Phoenix, Arizona. 5. Department of Medicine, University of California, San Francisco, California. 6. Department of Medicine, Mayo Clinic, Rochester, Minnesota. 7. Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. 8. Department of Medicine, University of Toronto, Toronto, Ontario, Canada. 9. Department of Medicine, Emory University, Atlanta, Georgia. 10. Department of Medicine, Mercy Medical Center, Baltimore, Maryland. 11. Department of Medicine, Virginia Commonwealth University and McGuire VA Medical Center, Richmond, Virginia. 12. Department of Biostatistics, Virginia Commonwealth University, Richmond, Virginia. 13. Microbiome Analysis center, George Mason University, Manassas, Virginia.
Abstract
BACKGROUND & AIMS: Inpatients with cirrhosis have high rates of acute-on-chronic failure (ACLF) development and high mortality within 30 days of admission to the hospital. Better biomarkers are needed to predict these outcomes. We performed metabolomic analyses of serum samples from patients with cirrhosis at multiple centers to determine whether metabolite profiles might identify patients at high risk for ACLF and death. METHODS: We performed metabolomic analyses, using liquid chromatography, of serum samples collected at time of admission to 12 North American tertiary hepatology centers from 602 patients in the North American Consortium for the Study of End-Stage Liver Disease sites from 2015 through 2017 (mean age, 56 years; 61% men; mean model for end-stage liver disease score, 19.5). We performed analysis of covariance, adjusted for model for end-stage liver disease at time of hospital admission, serum levels of albumin and sodium, and white blood cell count, to identify metabolites that differed between patients who did vs did not develop ACLF and patients who did vs did not die during hospitalization and within 30 days. We performed random forest analysis to identify specific metabolite(s) that were associated with outcomes and area under the curve (AUC) analyses to analyze them in context of clinical parameters. We analyzed microbiomes of stool samples collected from 133 patients collected at the same time and examined associations with serum metabolites. RESULTS: Of the 602 patients analyzed, 88 developed ACLF (15%), 43 died in the hospital (7%), and 72 died within 30 days (12%). Increased levels of compounds of microbial origin (aromatic compounds, secondary or sulfated bile acids, and benzoate) and estrogen metabolites, as well as decreased levels of phospholipids, were associated with development of ACLF, inpatient, and 30-day mortality and were also associated with fecal microbiomes. Random forest analysis and logistic regression showed that levels of specific microbially produced metabolites identified patients who developed ACLF with an AUC of 0.84 (95% confidence interval [CI] 0.78-0.88; P = .001), patients who died while in the hospital with an AUC of 0.81 (95% CI 0.74-0.85; P = .002), and patients who died within 30 days with an AUC of 0.77 (95% CI 0.73-0.81; P = .02). The metabolites were significantly additive to clinical parameters for predicting these outcomes. Metabolites associated with outcomes were also correlated with microbiomes of stool samples. CONCLUSIONS: In an analysis of serum metabolites and fecal microbiomes of patients hospitalized with cirrhosis at multiple centers, we associated metabolites of microbial origin and lipid moieties with development of ACLF and death as an inpatient or within 30 days, after controlling for clinical features.
BACKGROUND & AIMS: Inpatients with cirrhosis have high rates of acute-on-chronic failure (ACLF) development and high mortality within 30 days of admission to the hospital. Better biomarkers are needed to predict these outcomes. We performed metabolomic analyses of serum samples from patients with cirrhosis at multiple centers to determine whether metabolite profiles might identify patients at high risk for ACLF and death. METHODS: We performed metabolomic analyses, using liquid chromatography, of serum samples collected at time of admission to 12 North American tertiary hepatology centers from 602 patients in the North American Consortium for the Study of End-Stage Liver Disease sites from 2015 through 2017 (mean age, 56 years; 61% men; mean model for end-stage liver disease score, 19.5). We performed analysis of covariance, adjusted for model for end-stage liver disease at time of hospital admission, serum levels of albumin and sodium, and white blood cell count, to identify metabolites that differed between patients who did vs did not develop ACLF and patients who did vs did not die during hospitalization and within 30 days. We performed random forest analysis to identify specific metabolite(s) that were associated with outcomes and area under the curve (AUC) analyses to analyze them in context of clinical parameters. We analyzed microbiomes of stool samples collected from 133 patients collected at the same time and examined associations with serum metabolites. RESULTS: Of the 602 patients analyzed, 88 developed ACLF (15%), 43 died in the hospital (7%), and 72 died within 30 days (12%). Increased levels of compounds of microbial origin (aromatic compounds, secondary or sulfated bile acids, and benzoate) and estrogen metabolites, as well as decreased levels of phospholipids, were associated with development of ACLF, inpatient, and 30-day mortality and were also associated with fecal microbiomes. Random forest analysis and logistic regression showed that levels of specific microbially produced metabolites identified patients who developed ACLF with an AUC of 0.84 (95% confidence interval [CI] 0.78-0.88; P = .001), patients who died while in the hospital with an AUC of 0.81 (95% CI 0.74-0.85; P = .002), and patients who died within 30 days with an AUC of 0.77 (95% CI 0.73-0.81; P = .02). The metabolites were significantly additive to clinical parameters for predicting these outcomes. Metabolites associated with outcomes were also correlated with microbiomes of stool samples. CONCLUSIONS: In an analysis of serum metabolites and fecal microbiomes of patients hospitalized with cirrhosis at multiple centers, we associated metabolites of microbial origin and lipid moieties with development of ACLF and death as an inpatient or within 30 days, after controlling for clinical features.
Authors: Jasmohan S Bajaj; Guadalupe Garcia-Tsao; K Rajender Reddy; Jacqueline G O'Leary; Hugo E Vargas; Jennifer C Lai; Patrick S Kamath; Puneeta Tandon; Ram M Subramanian; Paul Thuluvath; Andrew Fagan; Tejasav Sehrawat; Randolph de la Rosa Rodriguez; Leroy R Thacker; Florence Wong Journal: Hepatology Date: 2021-07-08 Impact factor: 17.298
Authors: Mark M Davis; Pere Ginès; Elisa Pose; Elsa Solà; Juan J Lozano; Adrià Juanola; Julia Sidorova; Giacomo Zaccherini; Koos de Wit; Frank Uschner; Marta Tonon; Konstantin Kazankov; Cesar Jiménez; Daniela Campion; Laura Napoleone; Ann T Ma; Marta Carol; Manuel Morales-Ruiz; Carlo Alessandria; Ulrich Beuers; Paolo Caraceni; Claire Francoz; François Durand; Rajeshwar P Mookerjee; Jonel Trebicka; Victor Vargas; Salvatore Piano; Hugh Watson; Juan G Abraldes; Patrick S Kamath Journal: Hepatol Commun Date: 2021-12-28
Authors: Clara Depommier; Amandine Everard; Céline Druart; Dominique Maiter; Jean-Paul Thissen; Audrey Loumaye; Michel P Hermans; Nathalie M Delzenne; Willem M de Vos; Patrice D Cani Journal: Gut Microbes Date: 2021 Jan-Dec
Authors: Sung-Eun Kim; Ji Won Park; Hyung Su Kim; Myoung-Kuk Jang; Ki Tae Suk; Dong Joon Kim Journal: Int J Mol Sci Date: 2021-10-28 Impact factor: 5.923